Clinical Trial Update: An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib [Phase 3]

View source ↗

Summary

An extension Phase 3 study evaluating long-term efficacy, safety, and tolerability of remibrutinib in chronic spontaneous urticaria patients who completed prior…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• Remibrutinib (remibrutinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Spontaneous Urticaria | Phase 3 | Status: ACTIVE_NOT_RECRUITING